Efforts to copy biotech drugs face delays, obstacles
Published on February 28, 2013 at 2:46 AM
The Wall Street Journal: Biotech Drugs Still Won't Copy
Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings (Weaver, Whalen and Rockoff, 2/26).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.